Introduction：Basic information about CAS 108736-35-2|Lanreotide acetate salt, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lanreotide acetate salt |
|---|
| CAS Number | 108736-35-2 | Molecular Weight | 1096.323 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 1508.2±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C54H69N11O10S2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 865.9±34.3 °C |
|---|
Names
| Name | Lanreotide |
|---|
| Synonym | More Synonyms |
|---|
Lanreotide acetate salt BiologicalActivity
| Description | Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2]. |
|---|
| Related Catalog | Research Areas >>CancerResearch Areas >>EndocrinologySignaling Pathways >>Others >>Others |
|---|
| In Vitro | Lanreotide (BIM 23014) (100 nM; 24-48 h) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1]. Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2]. |
|---|
| In Vivo | Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage: 2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition. |
|---|
| References | [1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. [2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 1508.2±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C54H69N11O10S2 |
|---|
| Molecular Weight | 1096.323 |
|---|
| Flash Point | 865.9±34.3 °C |
|---|
| Exact Mass | 1095.467041 |
|---|
| PSA | 405.68000 |
|---|
| LogP | 2.89 |
|---|
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
|---|
| Index of Refraction | 1.689 |
|---|
| InChIKey | PUDHBTGHUJUUFI-HUZRFOFRSA-N |
|---|
| SMILES | CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O |
|---|
Synonyms
| B-naphthyl-D-ala-cys-tyr-D-trp*lys-val-cys-thr am |
| 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[1-(aminocarbonyl)-2-hydroxypropyl]-19-[[2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo- |
| 10-(4-Aminobutyl)-N-(1-amino-3-hydroxy-1-oxo-2-butanyl)-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide |
| Somatuline |
| AUTOGEL |
| ANGIOPEPTIN |
| IPSTYL |
| DC-13-116 |
| 10-(4-Aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide |
| H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2 |
